Scientific, Not Legal, Developments Are Key To Generic Biologics – McClellan
Generic drug firms can speed creation of a pathway for generic biologics by focusing on the science behind the products, former FDA commissioner Mark McClellan said
Generic drug firms can speed creation of a pathway for generic biologics by focusing on the science behind the products, former FDA commissioner Mark McClellan said